- our experts
- Student Sphere
- Hotel & Travel
Biomarkers are measurable indicators of biological processes or conditions that can be used to diagnose, monitor, or predict the course of disease. Biomarkers can include genetic, epigenetic, proteomic, or metabolomic markers, among others. The discovery and development of biomarkers is a critical step in the development of personalized medicine, as biomarkers can be used to identify patients who are more likely to respond to a particular treatment or who are at higher risk for a specific disease.
Biomarker discovery involves identifying and validating new biomarkers that are associated with specific disease states or treatment outcomes. This process typically involves a combination of preclinical and clinical studies, including studies of biomarker expression in tissue samples, studies of biomarker levels in blood or other bodily fluids, and studies of biomarker response to specific treatments or interventions.
Once potential biomarkers have been identified, they must be validated in larger clinical studies to demonstrate their utility in predicting disease outcomes or treatment responses. This validation process may involve studies in diverse patient populations or studies in combination with other biomarkers or clinical parameters.
The development of biomarkers can also involve the development of diagnostic or prognostic tests that can be used to guide treatment decisions or monitor disease progression. These tests may involve the use of imaging techniques, such as magnetic resonance imaging (MRI) or positron emission tomography (PET), or the use of blood or tissue-based tests to measure biomarker levels.
Overall, the discovery and development of biomarkers is a critical step in the development of personalized medicine, as it can help to identify patients who are more likely to benefit from a particular treatment and to develop more targeted and effective therapies for specific disease states.
Biomarker discovery and development is a critical component of the pharmaceutical and biotechnology industries, as it involves the identification and validation of biomarkers for various diseases and conditions, which can be used to improve diagnosis, monitor disease progression, and predict response to therapy. The global biomarker discovery and development market includes a range of services and technologies designed to support biomarker research, such as assay development, biomarker validation, and biomarker testing.
The global biomarker discovery and development market is expected to grow significantly in the coming years, driven by factors such as the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and advancements in biomarker technology.
According to a report by Market Research Future, the global biomarker discovery and development market is expected to reach USD 69.09 billion by 2025, at a compound annual growth rate (CAGR) of 13.44% during the forecast period. The market is segmented based on type, application, disease area, and region.
Based on type, the market is segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers segment dominated the market in 2020, accounting for the largest share of the global biomarker discovery and development market. The segment is driven by the increasing demand for biomarkers that can predict response to therapy and guide treatment decisions.
Based on application, the market is segmented into diagnostics development, drug discovery and development, personalized medicine, and others. The diagnostics development segment dominated the market in 2020, accounting for the largest share of the global biomarker discovery and development market. The segment is driven by the increasing demand for biomarkers that can improve diagnosis and monitoring of diseases.
Based on disease area, the market is segmented into oncology, cardiovascular diseases, neurology, immunology, and others. The oncology segment dominated the market in 2020, accounting for the largest share of the global biomarker discovery and development market. The segment is driven by the increasing demand for biomarkers that can improve diagnosis and monitoring of cancer.
North America dominated the global biomarker discovery and development market in 2020, followed by Europe and the Asia Pacific. The dominance of North America is attributed to the presence of a large number of pharmaceutical and biotechnology companies, the high healthcare expenditure, and the favorable regulatory environment.
The key players operating in the global biomarker discovery and development market include Thermo Fisher Scientific Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., and Agilent Technologies, Inc., among others. These companies are investing heavily in research and development activities to develop new and innovative biomarker technologies and gain a competitive edge.
Overall, the biomarker discovery and development market is expected to experience significant growth in the coming years, driven by the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and advancements in biomarker technology.
ALSO READ Drugs and Drug Targets Drug Discovery, Design and Development Pharmacokinetics and Pharmacodynamics Computer Aided Drug Design Drug Metabolism Pharmaceutical Biotechnology Combinatorial Chemistry Novel Drug Delivery Systems Formulations Natural Products Traditional Medicine Drug Repurposing and Drug Repositioning Precision Medicine Personalized Therapies Drug Development and Clinical Trials Biomarker Discovery and Development Biologics and Biosimilars Vaccines and Immunotherapies Steam Cells and Regenerative Medicine Drug Safety and Pharmacovigilance Pharmacogenomics Toxicology Rare Diseases Receptors as Target for Drug Discovery Drugs Affecting the Cardiovascular System Drugs Affecting the Central Nervous System Drugs Affecting Hormonal Systems Chemotherapeutic Agents Antibacterial Agents Antiviral Agents Anticancer Agents The Opioid Analgesics Anti-Ulcer Agents Non-Steroidal Anti Inflammatory Drugs Steroids Antibiotics Antineoplastic Agents Anthelmintics Sulphonamides Artificial Intelligence and Machine Learning in Drug Discovery and Development Genomics and Proteomics in Drug Discovery and Development Gene Therapy and Genome Editing in Treating Genetic Diseases Nanotechnology in Drug Delivery and Imaging Virtual and Augmented Reality in Drug Discovery and Development Patient Engagement and Patient-Centered Drug Development Big Data Analytics in Drug Discovery and Development
Toxicology Conferences Medicinal Chemistry Conferences 2023 Europe Traditional Medicine Conferences Medicinal Chemistry Conferences 2023 Natural Products Conferences Pharmaceutical Chemistry Conferences Pharmacology Conferences Drug Discovery Conferences 2023